Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Pharmaxis phase I trial attracts interest from multiple pharmaceutical companies

Final stages of phase I studies and phase II enabling toxicity studies are due to complete in Q3 2018.
lab worker
Initial results from phase I demonstrate best in class profile for LOXL2

Pharmaxis Ltd (ASX:PXS) has briefed potential partners attending the BIO18 partnering conference in Boston on data emerging from the phase I clinical studies of its anti‐fibrotic LOXL2 inhibitor program in which two compounds are showing significant inhibition of the enzyme for 24 hours with a single oral dose.  

LOXL2 or lysyl oxidase like 2 has been implicated as a key factor in various fibrotic diseases in organs such as the liver, lung, heart and kidney.

WATCH: Pharmaxis has the "secret sauce" for developing drugs through to commercialisation

Pharmaxis’ two compounds have both cleared the first stage of the studies where single oral doses of different strengths were trialled in healthy volunteers. 

There were no adverse safety findings in this first stage.   Both drugs are now entering the final stage where different fixed doses are given for 14 days.

In addition to studying their safety and pharmacokinetic profiles the two studies are also investigating the degree to which these drugs can inhibit the target enzyme LOXL2.

Importantly, Pharmaxis has been able to demonstrate a large and highly significant inhibition of this enzyme for a full 24 hours with a single oral dose.

Pharmaxis chief executive officer Gary Phillips said: “The data package being reviewed by several multinational pharmaceutical companies under confidentiality agreements is now maturing rapidly as we see the final data being generated by ongoing pre‐clinical and clinical studies. 

“There are a number of key features which have contributed to an increase in the already strong interest amongst these companies.”

The amine oxidase platform at Pharmaxis has generated small molecule enzyme inhibitors to a range of important disease targets that are at various stages of development. 

The SSAO inhibitor acquired by Boehringer is in phase II and the LOXL2 inhibitors are in phase I trials.

Meanwhile a compound inhibiting both myeloperoxidase (MPO) and SSAO and another compound inhibiting all the LOX family of enzymes are both in the final stages of pre‐clinical testing with phase I trials scheduled to commence in the next 6 to 12 months.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

Related Articles

nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
Lung X-Ray
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use